Preprocedural bowel prep can be a major barrier to outpatient colonoscopy compliance, especially for patients with high medical needs like the elderly and diabetic, resulting in an inadequately prepped colon. An inadequately prepped colon occurs in approximately 23% of outpatient colonoscopies and can often prolong procedure time, decrease cecal intubation rate, reduce adenoma and neoplasm detection, increase adverse events and lead to repeated procedures, all of which can put the patient at higher risk and result in increased costs.1
1: Hassan C. et.al., Clinical Gastroenterology and Hepatology, 2012;10:501-506
2: HRA Healthcare Research & Analytics - Market Research, May 2015
The Pure-Vu® System’s ability to facilitate rapid, intra-procedural cleaning of poorly prepped colons could potentially reduce the dependency on pre-procedural preparation to facilitate a quality exam. The Company presented cost analysis data at Digestive Disease Week® 2018 indicating the Pure-Vu® System has the potential to reduce inadequate colon prep rate for colonoscopy, which may lead to lower costs and lower projected incidence of colorectal cancer (CRC) in average and high-risk patients. Following the recent FDA clearance of the second generation Pure-Vu® System (“Pure-Vu® GEN2”), Motus GI plans to initiate its commercial launch in the U.S. with an initial focus on inpatient colonoscopy, with plans to expand into the high medical need outpatient market. The commercial launch of Pure-Vu® in international markets will be explored in the future.
1: HRA Healthcare Research & Analytics - Market Research, May 2015
2: Hassan C. et.al., Clinical Gastroenterology and Hepatology, 2012;10:501-506
3: Gralnek, I., The Pure-Vu Colon Cleansing System Reduces Lifetime Costs and Incidence of Colorectal Cancer (CRC) - A Cost Minimization Analysis; DDW Week® 2018